Histology
Squamous Cell Carcinoma
CI-CAN-00001550SCCExplore in graph →
976 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001550SCCExplore in graph →
Clinical trials
2,930 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (402)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00957853 | Preoperative Treatment With Cetuximab and/or IMC-A12 | completed | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT01044433 | Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck | completed | Phase 2 | 44 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT01697800 | A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract | completed | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 28, 2020 | clinicaltrials |
| NCT01362127 | Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia(NeoRes) | completed | Phase 2 | 181 | Karolinska University HospitalOTHER | 1 | Feb 26, 2020 | clinicaltrials |
| NCT01469429 | Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. | completed | Phase 1 / Phase 2 | 70 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 20, 2020 | clinicaltrials |
| NCT02882308 | Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.(OPHELIA) | completed | Phase 2 | 41 | Hellenic Cooperative Oncology GroupOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT01998542 | Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck(HNC) | completed | Phase 2 | 12 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 23, 2020 | clinicaltrials |
| NCT02335918 | A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 175 | Celldex TherapeuticsINDUSTRY | 1 | Dec 9, 2019 | clinicaltrials |
| NCT01631357 | Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer(CIK) | completed | Phase 2 / Phase 3 | 96 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT01774760 | Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer | completed | Phase 2 | 10 | Turku University HospitalOTHER_GOV | 1 | Oct 4, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT02794077 | Cyclophosphamide for Nasopharyngeal Carcinoma | completed | Phase 2 | 56 | The University of Hong KongOTHER | 0 | Oct 2, 2019 | clinicaltrials |
| NCT02339558 | Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 3 | Sep 13, 2019 | clinicaltrials |
| NCT02454179 | Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma(KEYNOTE147) | completed | Phase 2 | 78 | Acerta Pharma BVINDUSTRY | 1 | Sep 12, 2019 | clinicaltrials |
| NCT01581970 | Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer | completed | Phase 2 | 7 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 11, 2019 | clinicaltrials |
| NCT00126555 | Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Aug 30, 2019 | clinicaltrials |
| NCT01266447 | Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT00025233 | Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00416455 | Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer | completed | Phase 1 / Phase 2 | 384 | National Cancer Institute (NCI)NIH | 4 | Jul 23, 2019 | clinicaltrials |
| NCT00389727 | Simultaneous Integrated Boost (SIB)- IMRT | completed | Phase 2 | 22 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Jul 15, 2019 | clinicaltrials |
| NCT01016769 | Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) | completed | Phase 1 / Phase 2 | 48 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 26, 2019 | clinicaltrials |
| NCT00894413 | A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract | completed | Phase 2 | 45 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT02649361 | Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102) | completed | Phase 2 | 164 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 5, 2019 | clinicaltrials |
| NCT03584308 | Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal | completed | Phase 2 | 110 | Catalysis SLINDUSTRY | 1 | May 22, 2019 | clinicaltrials |
| NCT02123511 | Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy | completed | Phase 2 | 34 | Mayo ClinicOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT01267253 | Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Mar 20, 2019 | clinicaltrials |
| NCT00652080 | An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS) | completed | Phase 1 / Phase 2 | 35 | BPGbioINDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01831531 | Study of S-1 in Combination With Radiotherapy in Esophageal Cancer | completed | Phase 2 | 105 | Fudan UniversityOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT00309959 | ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 37 | Gynecologic Oncology GroupNETWORK | 1 | Jan 8, 2019 | clinicaltrials |
| NCT01696955 | Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery | completed | Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Dec 19, 2018 | clinicaltrials |
| NCT00500760 | Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer | completed | Phase 2 | 153 | AmgenINDUSTRY | 0 | Oct 17, 2018 | clinicaltrials |
| NCT00055913 | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 1 / Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Oct 2, 2018 | clinicaltrials |
| NCT01941992 | Role of SAMITAL® in the Relief of Chemo-radiation (CT-RT) Induced Oral Mucositis in Head and Neck Cancer Patients(ROSAM) | completed | Phase 2 | 120 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Sep 13, 2018 | clinicaltrials |
| NCT01218048 | ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 40 | Robert FerrisOTHER | 1 | Aug 16, 2018 | clinicaltrials |
| NCT02048020 | Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer | completed | Phase 2 | 26 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 14, 2018 | clinicaltrials |
| NCT01557959 | Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 45 | Wake Forest University Health SciencesOTHER | 1 | Jun 29, 2018 | clinicaltrials |
| NCT01204099 | Study of PX-866 and Docetaxel in Solid Tumors | completed | Phase 1 / Phase 2 | 223 | Cascadian Therapeutics Inc.INDUSTRY | 2 | May 16, 2018 | clinicaltrials |
| NCT01285778 | Vectibix for the Treatment of Anal Cancer(VITAL) | completed | Phase 2 | 58 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | May 16, 2018 | clinicaltrials |
| NCT00369122 | Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 2 | Mar 20, 2018 | clinicaltrials |
| NCT01642082 | Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 28 | Gynecologic Oncology GroupNETWORK | 1 | Mar 13, 2018 | clinicaltrials |
| NCT01316757 | Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer | completed | Phase 2 | 24 | Fox Chase Cancer CenterOTHER | 1 | Feb 26, 2018 | clinicaltrials |
| NCT01612546 | Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery | completed | Phase 2 | 10 | City of Hope Medical CenterOTHER | 1 | Feb 1, 2018 | clinicaltrials |
| NCT00408694 | Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 2 | Jan 30, 2018 | clinicaltrials |
| NCT00661427 | Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer | completed | Phase 2 | 61 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 11, 2018 | clinicaltrials |
| NCT00041093 | Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 27 | Gynecologic Oncology GroupNETWORK | 1 | Jan 10, 2018 | clinicaltrials |
| NCT01178944 | Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer | completed | Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Dec 13, 2017 | clinicaltrials |
| NCT00888173 | Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 45 | Gynecologic Oncology GroupNETWORK | 1 | Dec 6, 2017 | clinicaltrials |
| NCT01195922 | Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma | completed | Phase 1 / Phase 2 | 37 | National Institute of Dental and Craniofacial Research (NIDCR)NIH | 1 | Dec 6, 2017 | clinicaltrials |
| NCT00068406 | Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva | completed | Phase 2 | 61 | Gynecologic Oncology GroupNETWORK | 1 | Nov 20, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Mar 19, 2020source: clinicaltrials